Antimicrobial activity of ceftaroline combined with avibactam tested against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2010–2012)

Castanheira, 2012, Activity of ceftaroline-avibactam tested against gram-negative organism populations, including strains expressing one or more beta-lactamases and methicillin-resistant Staphylococcus aureus carrying various SCCmec types, Antimicrob Agents Chemother, 56, 4779, 10.1128/AAC.00817-12 Castanheira, 2013, Prevalence of β-lactamase encoding genes among Enterobacteriaceae bacteremia isolates collected in 26 USA hospitals: report from the SENTRY Antimicrobial Surveillance Program (2010), Antimicrob Agents Chemother, 57, 3012, 10.1128/AAC.02252-12 Castanheira, 2014, Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine United States census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups, Antimicrob Agents Chemother, 10.1128/AAC.01896-13 Clinical and Laboratory Standards Institute (CLSI), 2012 Clinical and Laboratory Standards Institute (CLSI), 2013 Dryden, 2010, Complicated skin and soft tissue infection, J Antimicrob Chemother, 65, iii35 Ehmann, 2012, Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor, Proc Natl Acad Sci U S A, 109, 11663, 10.1073/pnas.1205073109 EUCAST Breakpoint tables for interpretation of MICs and zone diameters. Version 3.0, January 2013. Available at http://www.eucast.org/clinical_breakpoints/. Accessed January 2, 2013. Flamm, 2012, Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program, Antimicrob Agents Chemother, 56, 2933, 10.1128/AAC.00330-12 Giordano, 2007, Skin and skin structure infections: treatment with newer generation fluoroquinolones, Ther Clin Risk Manag, 3, 309, 10.2147/tcrm.2007.3.2.309 Goldstein, 2013, Comparative in vitro activity of ceftaroline, ceftaroline-avibactam, and other antimicrobial agents against aerobic and anaerobic bacteria cultured from infected diabetic foot wounds, Diagn Microbiol Infect Dis, 76, 347, 10.1016/j.diagmicrobio.2013.03.019 Livermore, 2012, Characterization of beta-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104), J Antimicrob Chemother, 67, 1354, 10.1093/jac/dks079 Moet, 2007, Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998–2004), Diagn Microbiol Infect Dis, 57, 7, 10.1016/j.diagmicrobio.2006.05.009 Mushtaq, 2010, Activity of chequerboard combinations of ceftaroline and NXL104 versus beta-lactamase-producing Enterobacteriaceae, J Antimicrob Chemother, 65, 1428, 10.1093/jac/dkq161 Sader, 2013, Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010), Diagn Microbiol Infect Dis, 76, 61, 10.1016/j.diagmicrobio.2013.01.005 Sader, 2013, Antimicrobial activity of ceftaroline-avibactam tested against recent clinical isolates from USA medical centers (2010–2011), Antimicrob Agents Chemother, 57, 1982, 10.1128/AAC.02436-12 Saravolatz, 2011, Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus, Clin Infect Dis, 52, 1156, 10.1093/cid/cir147 Stevens, 2005, Practice guidelines for the diagnosis and management of skin and soft-tissue infections, Clin Infect Dis, 41, 1373, 10.1086/497143 Teflaro® Package Insert Tygacil® Package Insert Wiskirchen, 2011, In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against ESBL- and non-ESBL-producing Enterobacteriaceae, Antimicrob Agents Chemother, 55, 3220, 10.1128/AAC.00024-11 ZinforoTM Package Insert